A randomized, placebo-controlled trial of selenium supplementation in patients with type 2 diabetes: Effects on glucose homeostasis, oxidative stress, and lipid profile

American Journal of Therapeutics

Volumn 21, Issue 6, 2014, Pages 491-495

  Faghihi, Toktam ^a,b   Radfar, Mania ^a,c   Barmal, Maedeh ^a   Amini, Peyvand ^c   Qorbani, Mostafa ^d,e   Abdollahi, Mohammad ^a   Larijani, Bagher ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ALBORZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes; Lipid profile; Oxidative stress; Plasma glucose; Selenium

Indexed keywords

ANTIOXIDANT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIPID; SELENIUM;

ADVERSE EFFECTS; BLOOD; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ANTIOXIDANTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; LIPIDS; MALE; MIDDLE AGED; OXIDATIVE STRESS; SELENIUM;

EID: 84914155025     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318269175f     Document Type: Article

References (33)

1. Holben DH, Smith AM. The diverse role of selenium within selenoproteins: a review. J Am Diet Assoc. 1999; 99:836-843.
2. Stranges S, Navas-Acien A, Rayman MP, et al. Selenium status and cardiometabolic health: state of the evidence. Nutr Metab Cardiovasc Dis. 2010;20:754-760.
3. Stranges S, Galletti F, Farinaro E. Associations of selenium status with cardiometabolic risk factors: an 8-year follow-up analysis of the Olivetti Heart Study. Atherosclerosis. 2011;217:274-278.
4. Stranges S, Marshall JR, Natarajan R, et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes. Ann Intern Med. 2007;147:217-223.
5. Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all-cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med. 2008;168:404-410.
6. Bleys J, Navas-Acien A, Laclaustra M, et al. Serum selenium and peripheral arterial disease: results from the national health and nutrition examination survey, 2003-2004. Am J Epidemiol. 2009;169:996-1003.
7. Rayman MP, Stranges S, Griffin BA, et al. Effect of supplementation with high-selenium yeast on plasma lipids: a randomized trial. Ann Intern Med. 2011;154: 656-665.
8. Rajpathak S, Rimm E, Morris JS, et al. Toenail selenium and cardiovascular disease in men with diabetes. J Am Coll Nutr. 2005;24:250-256.
9. Navarro-Alarcón M, López-G de la Serrana H, Perez-Valero V, et al. Serum and urine selenium concentrations as indicators of body status in patients with diabetes mellitus. Sci Total Environ. 1999;22:79-85.
10. Kljai K, Runje R. Selenium and glycogen levels in diabetic patients. Biol Trace Elem Res. 2001;83:223-229.
11. Whiting PH, Kalansooriya A, Holbrook I, et al. The relationship between chronic glycaemic control and oxidative stress in type 2 diabetes mellitus. Br J Biomed Sci. 2008;65:71-74.
12. Kornhauser C, Garcia-Ramirez JR, Wrobel K, et al. Serum selenium and glutathione peroxidase concentrations in type 2 diabetes mellitus patients. Prim Care Diabetes. 2008;2:81-85.
13. Wiernsperger N, Rapin JR. Trace elements in glucometa-bolic disorders: an update. Diabetol Metab Syndr. 2010;2:70.
14. Rahimi R, Nikfar S, Larijani B, et al. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59:365-373.
15. Bartlett HE, Eperjesi F. Nutritional supplementation for type 2 diabetes: a systematic review. Ophthalmic Physiol Opt. 2008;28:503-523.
16. Maritim AC, Sanders RA, Watkins JB III. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003;17:24-38.
17. Kähler W, Kuklinski B, Rühlmann C, et al. Diabetes mellitus-a free radical-associated disease. Results of adjuvant antioxidant supplementation [Abstract]. Z Gesamte Inn Med. 1993;48:223-232.
18. Faure P, Ramon O, Favier A, et al. Selenium supplementation decreases nuclear factor-kappa B activity in peripheral blood mononuclear cells from type 2 diabetic patients. Eur J Clin Invest. 2004;34:475-481.
19. Astaneie F, Afshari M, Mojtahedi A, et al. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch Med Res. 2005;36:376-381.
20. Inam R, Ekmekci G, Somer G. Differential pulse polarographic determination of selenium (IV) in whole blood using the catalytic hydrogen wave. Talanta. 2000;51:825-830.
21. Safaralizadeh R, Kardar GA, Pourpak Z, et al. Serum concentration of selenium in healthy individuals living in Tehran. Nutr J. 2005;4:32-36.
22. Algotar AM, Stratton MS, Stratton SP, et al. No effect of selenium supplementation on serum glucose levels in men with prostate cancer. Am J Med. 2010;123:765-768.
23. Czernichow S, Couthouis A, Bertrais S, et al. Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. Am J Clin Nutr. 2006;84:395-399.
24. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009;301:39-51.
25. Bleys J, Navas-Acien A, Guallar E. Serum selenium and diabetes in U.S. adults. Diabetes Care. 2007;30:829-834.
26. Laclaustra M, Navas-Acien A, Stranges S, et al. Serum selenium concentrations and diabetes in U.S. adults: national health and nutrition examination survey (NHANES) 2003-2004. Environ Health Perspect. 2009;117:1409-1413.
27. Stranges S, Sieri S, Vinceti M, et al. A prospective study of dietary selenium intake and risk of type 2 diabetes. BMC Public Health. 2010;10:564.
28. Akbaraly TN, Arnaud J, Rayman MP, et al. Plasma selenium and risk of dysglycemia in an elderly French population: results from the prospective Epidemiology of Vascular Ageing Study. Nutr Metab. 2010;18:7-21.
29. Misu H, Takamura T, Takayama H, et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 2010;12:483-495.
30. Yang SJ, Hwang SY, Choi HY, et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab. 2011;96:E1325-E1329.
31. Roman M, Lapolla A, Jitaru P, et al. Plasma selenopro-teins concentrations in type 2 diabetes mellitus-a pilot study. Transl Res. 2010;156:242-250.
32. Steinbrenner H, Speckmann B, Pinto A, et al. High selenium intake and increased diabetes risk: experimental evidence for interplay between selenium and carbohydrate metabolism. J Clin Biochem Nutr. 2011;48:40-45.
33. Laclaustra M, Stranges S, Navas-Acien A, et al. Serum selenium and serum lipids in US adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Atherosclerosis. 2010;210:643-648.